Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination

NCT03466450 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.

NCT NCT03466450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03466450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination
Lead sponsor
Grupo Español de Investigación en Neurooncología
Phase
Phase 1/2
Overall status
Completed
Start date
March 15, 2018
Completion date
November 29, 2023
Enrollment
75 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma